Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 14/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15725087 | 1.00 | GLS (0.74) | GLSRECQLALDH1A1MEN1KMT2A | |
| SCHEMBL15725094 | 0.98 | GLS (0.78) | GLSRECQLALDH1A1CCNE1CDK2 | |
| SCHEMBL15725008 | 0.98 | GLS (0.78) | GLSRECQLALDH1A1CCNE1CDK2 | |
| SCHEMBL17172606 | 0.97 | GLS (0.80) | GLSRECQLALDH1A1MEN1KMT2A | |
| SCHEMBL21325659 | 0.96 | GLS (0.67) | GLSRECQLALDH1A1MEN1KMT2A | |
| SCHEMBL15725064 | 0.96 | GLS (0.77) | GLSMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL17172578 | 0.95 | GLS (0.84) | GLSRECQLALDH1A1CCNE1CDK2 | |
| SCHEMBL17172609 | 0.95 | GLS (0.84) | GLSRECQLALDH1A1CCNE1CDK2 | |
| SCHEMBL17172598 | 0.93 | GLS (0.83) | GLSKMT2A | |
| SCHEMBL16887441 | 0.91 | GLS (0.69) | GLSRECQLMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885RECQL 1267/4885ALDH1A1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.